A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response

PURPOSE: Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed in 70–80% and in approxim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Robbins, Paul F., Kassim, Sadik H., Tran, Thai Lan N., Crystal, Jessica S., Morgan, Richard A., Feldman, Steven A., Yang, James C., Dudley, Mark E., Wunderlich, John R., Sherry, Richard M., Kammula, Udai S., Hughes, Marybeth S., Restifo, Nicholas P., Raffeld, Mark, Lee, Chyi-Chia Richard, Li, Yong F., El-Gamil, Mona, Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361810/
https://ncbi.nlm.nih.gov/pubmed/25538264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2708
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados